Check Cap Ltd

Check Cap Ltd(CHEK)の株式分析

$1.610

+0.031 (+1.90%)終値時点

Loading chart…
High
1.675
Open
1.570
VWAP
1.59
Vol
58.97K
Mkt Cap
11.46M
Low
1.500
Amount
94.04K
EV/EBITDA, TTM
0.00

Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.

check-cap.com

Analyst Ratings (3)

Buy
3 Buy
0 Hold
0 Sell
Current: 1.61
安値
平均
高値

HC Wainwright & Co.

2023-06-07

目標株価

Hold

HC Wainwright & Co.

2023-05-15

目標株価

$7

Strong Buy

HC Wainwright & Co.

2023-04-05

目標株価

$7

Strong Buy

HC Wainwright & Co.

2021-08-09

目標株価

Strong Buy

Dawson James

2021-03-17

目標株価

Hold

バリュエーション指標

The current forward P/E ratio for Check Cap Ltd (CHEK) is 0.00, compared to its 5-year average forward P/E of -2.37.

Forward P/E

Overvalued
5Y Average P/E
-2.37
Current P/E
0.00
割高
-0.86
割安
-3.89

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
割高
0.00
割安
0.00

Forward P/S

Overvalued
5Y Average P/S
0.00
Current P/S
0.01
割高
0.01
割安
-0.00

Alphio AI Price Scenarios for CHEK

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CHEK

$0.90

シナリオ価格

B

Base

Base · 50%CHEK

$0.84

シナリオ価格

B

Bear

Bear · 25%CHEK

$0.80

シナリオ価格

CHEK FAQ — answered by Alphio AI

Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon. It operates in the Healthcare sector (X- RAY APPARATUS AND TUBES AND RELATED IRRADIATION industry).

3 analysts cover CHEK: 3 rate it Buy, 0 Hold and 0 Sell.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める